TNF Pharmaceuticals Files 2024 DEF 14A
Ticker: QCLS · Form: DEF 14A · Filed: Apr 21, 2025 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | DEF 14A |
| Filed Date | Apr 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, executive-compensation, corporate-history
TL;DR
TNF Pharma's 2024 proxy statement is in, detailing exec pay and governance. Formerly MyMD/Akers.
AI Summary
TNF Pharmaceuticals, Inc. filed its DEF 14A on April 21, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and corporate governance matters. Notably, the company previously operated under the names MyMD Pharmaceuticals, Inc. and Akers Biosciences, Inc., with the most recent name change occurring on April 20, 2021.
Why It Matters
This filing provides crucial information for shareholders regarding executive compensation, board structure, and other governance details, impacting investor confidence and decision-making.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the company's history of name changes and the nature of its business in the pharmaceutical sector can introduce inherent risks.
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Filer
- MyMD Pharmaceuticals, Inc. (company) — Former Company Name
- Akers Biosciences, Inc. (company) — Former Company Name
- 2024-12-31 (date) — Fiscal Year End
- 20250421 (date) — Filing Date
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a proxy statement, is used to solicit shareholder votes on important corporate matters, such as the election of directors and executive compensation.
When was TNF Pharmaceuticals, Inc. previously known by other names?
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. (name change on 20210420) and Akers Biosciences, Inc. (name change on 20170413).
What is the fiscal year end for the period covered by this filing?
The conformed period of report for this filing is 20241231, indicating the fiscal year ended on December 31, 2024.
Where is TNF Pharmaceuticals, Inc. headquartered?
The company's business and mailing address is 1185 Avenue of the Americas, Suite 249, New York, NY 10036.
What is the Standard Industrial Classification (SIC) code for TNF Pharmaceuticals, Inc.?
The SIC code for TNF Pharmaceuticals, Inc. is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 regarding TNF Pharmaceuticals, Inc. (QCLS).